NCT00050297

Brief Summary

The purpose of this study is to determine the optimal dosage of YM598 for slowing down disease progression in patients with rising PSA after initial therapy for localized prostate cancer.

Trial Health

45
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
7 countries

23 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 3, 2002

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 4, 2002

Completed
1.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2004

Completed
Last Updated

June 7, 2012

Status Verified

June 1, 2012

First QC Date

December 3, 2002

Last Update Submit

June 6, 2012

Conditions

Interventions

YM598DRUG

Sponsors & Collaborators

Study Sites (23)

University Clinic AZ

Brussels, Belgium

Location

University Clinic UCL St. Luc

Brussels, Belgium

Location

Private Urology Out-patient Ward

Jablonec nad Nisou, Czechia

Location

Clinic of Urology, University Hospital

Králové, Czechia

Location

Clinic of Urology, University Hospital

Olomouc, Czechia

Location

Clinic of Urology, University Hospital

Prague, Czechia

Location

Hôpital Bichat, service de Urology

Paris, France

Location

Haingasse 22

Bad Homburg, 61348, Germany

Location

Klinik und Poliklinik für Urologie, Universitätsklinikum Carl-Gustav-Carus

Dresden, Germany

Location

Klinik u. Poliklinik für Urologie, Philipps Universität, Baldingerstraße

Marburg, Germany

Location

Krummbogen 15

Marburg, Germany

Location

Regional Hospital, Department of Urology

Bydgoszcz, Poland

Location

MedSource Poland

Gdansk, Poland

Location

Bielanski Hospital, Department of Urology

Warsaw, Poland

Location

Oncology Center, Department of Urinary Tract Cancer

Warsaw, Poland

Location

Medical University, Clinic of Urology

Wroclaw, Poland

Location

Complejo Hospitaliaro Juan Canalejo, Servicio de Urología

Corunna, Spain

Location

Fundacion Hospital Alcorcón, Servicio Urología

Madrid, Spain

Location

Hospital Universitario Principe de Asturias, Servicio de Urología, Ctra.

Madrid, Spain

Location

Department of Urology, Bristol Royal Infirmary

Bristol, United Kingdom

Location

Department of Urology, Gartnavel Hospital

Glasgow, United Kingdom

Location

Department of Urology, Norfolk & Norwich Hospital

Norwich, United Kingdom

Location

Department of Urology, Taunton & Somerset Hospital

Taunton, United Kingdom

Location

MeSH Terms

Conditions

Prostatic Neoplasms

Interventions

N-(6-methoxy-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl)-2-phenylethenesulfonamide

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital Diseases

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

December 3, 2002

First Posted

December 4, 2002

Study Completion

February 1, 2004

Last Updated

June 7, 2012

Record last verified: 2012-06

Locations